Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb / CDK9 inhibitor. Atuveciclib (BAY-1143572) inhibits CDK9 / CycT1 with an IC 50 of 13 nM. Appearance:Solid IC50& Target:CDK9/CycT1 13 nM (IC 50 ) CDK9/CycT1(h) 6 nM (IC 50 ) CDK3/CycE(h) 890 nM (IC 50 ) CDK2/CycE(h) 1000 nM (IC 50 ) CDK1/CycB(h) 1100 nM (IC 50 ) CDK5/p35(h) 1600 nM (IC 50 ) In Vitro:Positive transcription elongation factor b (PTEFb) is a heterodimer of CDK9 and one of four cyclin partners, cyclin T1, cyclin K, cyclin T2a or cyclin T2b. Atuveciclib (BAY-1143572) demonstrates potent antiproliferative activity against HeLa cells (IC 50 In Vivo:In vivo efficacy studies in the MOLM-13 xenograft model in mice, Atuveciclib (BAY-1143572) demonstrates great potency and high antitumor efficacy. Daily administration of Atuveciclib (BAY-1143572) at 6.25 or 12.5mg/kg results in a dose-dependent antitumo Biological Activity:Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb / CDK9 inhibitor. Atuveciclib (BAY-1143572) inhibits CDK9 / CycT1 with an IC 50 of 13 nM.
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
Atuveciclib
CAS number：unknown molecular formula：C18H18FN5O2S
overview
compound introduction
Specs
| Chinese alias | 阿图韦西尼 | ||
| English alias | - | ||
| CAS number | unknown | molecular formula | C18H18FN5O2S |
| molecular weight | 387.43 g/mol | Exact mass | ≥99% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
